2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 318

HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Abstract Number: 82

HLA-DPB1^*04:01 Confers Risk for PR3-ANCA Positive ANCA-Associated Vasculitis (AAV), but Protects Against MPO-ANCA Positive AAV, in a Japanese Population
Abstract Number: 775

HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis: Literature Review and Meta-Analysis
Abstract Number: 1787

HLA-DRB1*01 Is Associated with Henoch- Schönlein Purpura in the Spanish Population
Abstract Number: 1900

HLA-DRB1*1101, Regulatory Variants of the MHC, and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis
Abstract Number: 644

HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis and Extends Life Spans in Lupus Prone MRL/Lpr Mice
Abstract Number: 190

Hospital Volume Predicts Outcomes and Complications after Total Shoulder Arthroplasty
Abstract Number: 800

Hospitalization Rates and Utilization Among Patients with Giant Cell Arteritis: A Population-Based Study from 1987 to 2012
Abstract Number: 2116

Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to 2012
Abstract Number: 2043

How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists?
Abstract Number: 2544

How Does a Younger Age at the Onset of Sjögren’s Syndrome (pSS) Influence the Clinical Presentation and the Clinical Course of the Disease?
Abstract Number: 2257

How Does Non-Compliance to Prolia ® (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients?
Abstract Number: 1061

How Does Rheumatoid Arthritis Disease Activity Affect Development of Upper Cervical Lesions? a Retrospective Study of Cervical Spine X-Rays Combined with a Cohort Study in Rheumatoid Arthritis Patients
Abstract Number: 701

How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study
Abstract Number: 906

How Long Does Sonographic Joint Activity Continue in Clinically Remittive Joints of Patients with Rheumatoid Arthritis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].